	Application No.	Applicant(s)
Notice of Allowability	••	•
	09/885,297 Examiner	INGRAM ET AL. Art Unit
	•	
	Manjunath N. Rao, Ph.D.	1652
The MAILING DATE of this communication appears on the cover sheet with the correspondence address All claims being allowable, PROSECUTION ON THE MERITS IS (OR REMAINS) CLOSED in this application. If not included herewith (or previously mailed), a Notice of Allowance (PTOL-85) or other appropriate communication will be mailed in due course. THIS NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RIGHTS. This application is subject to withdrawal from issue at the initiative of the Office or upon petition by the applicant. See 37 CFR 1.313 and MPEP 1308.		
1. This communication is responsive to the amendment filed on 5-2-05.		
2. X The allowed claim(s) is/are 44-49,51-59,111 and 112.		
3. X The drawings filed on 19 June 2001 are accepted by the Examiner.		
 4. Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some* c) None of the: 1. Certified copies of the priority documents have been received. 2. Certified copies of the priority documents have been received in Application No. 3. Copies of the certified copies of the priority documents have been received in this national stage application from the International Bureau (PCT Rule 17.2(a)). * Certified copies not received: 		
Applicant has THREE MONTHS FROM THE "MAILING DATE" of this communication to file a reply complying with the requirements noted below. Failure to timely comply will result in ABANDONMENT of this application. THIS THREE-MONTH PERIOD IS NOT EXTENDABLE.		
5. A SUBSTITUTE OATH OR DECLARATION must be submitted. Note the attached EXAMINER'S AMENDMENT or NOTICE OF INFORMAL PATENT APPLICATION (PTO-152) which gives reason(s) why the oath or declaration is deficient.		
 6. CORRECTED DRAWINGS (as "replacement sheets") must be submitted. (a) including changes required by the Notice of Draftsperson's Patent Drawing Review (PTO-948) attached 1) hereto or 2) to Paper No./Mail Date (b) including changes required by the attached Examiner's Amendment / Comment or in the Office action of Paper No./Mail Date 		
Identifying indicia such as the application number (see 37 CFR 1.84(c)) should be written on the drawings in the front (not the back) of each sheet. Replacement sheet(s) should be labeled as such in the header according to 37 CFR 1.121(d).		
7. DEPOSIT OF and/or INFORMATION about the deposit of BIOLOGICAL MATERIAL must be submitted. Note the attached Examiner's comment regarding REQUIREMENT FOR THE DEPOSIT OF BIOLOGICAL MATERIAL.		
 Attachment(s) 1. ☑ Notice of References Cited (PTO-892) 2. ☐ Notice of Draftperson's Patent Drawing Review (PTO-948) 3. ☑ Information Disclosure Statements (PTO-1449 or PTO/SB/06 Paper No./Mail Date 6-30-03 4. ☐ Examiner's Comment Regarding Requirement for Deposit of Biological Material 	6. ☐ Interview Summary (Paper No./Mail Date 8), 7. ☐ Examiner's Amendm	e .

Application/Control Number: 09/885,297

Art Unit: 1652

DETAILED ACTION

Claims 44-49, 51-59, 111-112 are currently pending and are present for examination.

Applicants' amendments and arguments filed on 5-2-05, have been fully considered and are deemed to be persuasive to overcome the rejections previously applied. Rejections and/or objections not reiterated from previous office actions are hereby withdrawn.

Drawings

Drawings submitted in this application are accepted by the Examiner for examination purposes only.

Priority _____

Applicant's claim for domestic priority under 35 U.S.C. 119(e) is acknowledged.

Allowable Subject Matter

Claims 44-49, 51-59, 111-112 are allowed.

The following is an examiner's statement of reasons for allowance: Following a diligent search it was determined that the prior art neither teaches nor suggests a recombinant cell suitable for degradation of an oligosaccharide, wherein said recombinant cell comprises polynucleotides *celZ* and *celY* isolated from *Erwinia* encoding the polypeptides EGZ and EGY, capable of acting in synergy as claimed in claims 44-49, 51-59, 111-112. While the endoglucanases from *Erwinia* were known, it was determined that their action in synergy was not disclosed in the prior art and that is what renders this instant invention non-obvious.

Application/Control Number: 09/885,297

Art Unit: 1652

Any comments considered necessary by applicant must be submitted no later than the

payment of the issue fee and, to avoid processing delays, should preferably accompany the issue

fee. Such submissions should be clearly labeled "Comments on Statement of Reasons for

Allowance."

Any inquiry concerning this communication or earlier communications from the

Examiner should be directed to Manjunath N. Rao, Ph.D. whose telephone number is 571-272-

0939. The Examiner can normally be reached on 7.00 a.m. to 3.30 p.m. If attempts to reach the

examiner by telephone are unsuccessful, the Examiner's supervisor, Ponnathapura

Achutamurthy can be reached on 571-272-0928. The fax phone numbers for the organization

where this application or proceeding is assigned is 571-273-8300 for regular communications

and for After Final communications. Any inquiry of a general nature or relating to the status of

this application or proceeding should be directed to the receptionist whose telephone number is

571-272-1600.

Primary Examiner

Art Unit 1652

May 25, 2005

Page 3